Clinical trial
Flibanserin Versus Placebo in Premenopausal Women With HSDD
NCT00491829 · Sprout Pharmaceuticals, Inc, Industry · Completed
Key facts
| NCT number | NCT00491829 |
|---|---|
| Title | Flibanserin Versus Placebo in Premenopausal Women With HSDD |
| Official title | A Twenty-Four Week, Randomized, Double-Blind, Placebo Controlled, Safety and Efficacy Trial of Flibanserin 50 Milligrams Daily and 100 Milligrams Daily in Premenopausal European Women With Hypoactive Sexual Desire Disorder |
| Lead sponsor | Sprout Pharmaceuticals, Inc, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Sexual Dysfunctions, Psychological |
| Intervention type | Drug |
| Interventions | 50 mg qhs, 100 mg, placebo |
| Enrollment | 945 |
| Start date | Jun 1, 2007 |
| Primary completion | Mar 1, 2009 |
| Completion | Mar 1, 2009 |
| First posted | Jun 26, 2007 |
| Last update posted | Jun 2, 2014 |
| Countries | Austria, Belgium, Czechia, Finland, France, Germany, Hungary, Italy, Netherlands, Norway, Spain, Sweden and 1 more |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: